

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

CLEARBRIDGE BIOMEDICS PTE LTD SECURES FUNDING COMMITMENTS OF S\$6.6 MILLION

The board of directors ("**Board**") of Clearbridge Health Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that its 39.70%-owned associated company, Clearbridge BioMedics Pte. Ltd., ("**CBB**") has secured commitments of S\$6.6 million in funding ahead of its potential listing (the "**Potential Listing**"). CBB is principally engaged in research and experimental development on biotechnology, life and medical science and specialises in the area of cancer diagnostics solutions.

A copy of the Press Release issued by CBB in relation to the funding ahead of the Potential Listing can be found in Annex A attached herein.

The Board wishes to highlight that the Potential Listing is at a preliminary stage and is dependent on, *inter alia*, the results of preparatory work to be undertaken and requisite approvals/consents from the relevant regulatory authorities being obtained. As at the date of this announcement, CBB has not appointed any professional parties to advise on the Potential Listing. Accordingly, there is no assurance that the Potential Listing will proceed in due course.

The Company will announce any material development on the Potential Listing as and when appropriate.

Shareholders and other investors are reminded to exercise caution when dealing in securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisors if they are in doubt about the actions they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

28 June 2018

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898*

ANNEX A



Press Release - For Immediate Release

**CLEARBRIDGE BIOMEDICS INKS PRE-IPO FUNDING, MOVES TOWARDS
DEVELOPING END-TO-END DIAGNOSTIC TESTS**

- **The pre-IPO funding round attracted investments from oncology medical professionals as well as investors focused in healthcare and biotechnology**
- **Funds will be used for business expansion, technology development, talent recruitment and IPO-related expenses to develop end-to-end cancer diagnostic tests**
- **Barring unforeseen circumstances, the Company's IPO is expected to be launched in the last quarter of 2018**

Singapore, 28 June 2018 – Singapore-based medical technology company, **Clearbridge BioMedics Pte Ltd** ("**Clearbridge BioMedics**" or "**the Company**"), a cancer diagnostics solutions company, is pleased to announce that it has attracted S\$6.6 million in pre-IPO funding.

Pioneering patented, award-winning microfluidics technology, Clearbridge BioMedics is leading the advancement of non-invasive liquid biopsy for real time analysis of cancer cells, providing vital and accurate information for higher standard of healthcare treatment in an era of precision medicine. In addition, unlike conventional diagnostic treatments, Clearbridge BioMedics's cancer diagnostics solutions can potentially lower medical costs and at the same time, reduce inconvenience for patients.

This pre-IPO funding follows major milestones the Company has achieved, including:

- Spin-off from National University of Singapore and Singapore-MIT Alliance for Research and Technology (SMART Centre), backed by the Singapore government's National Research Foundation
- Pioneered a novel method for isolating cancer cells from a simple standard blood draw through technology that is non-invasive, while providing real-time information on cancer
- Successful commercialization of its ClearCell[®] FX1 System in 2015 with global deployments in leading cancer institutes and hospitals
- Attained various industry certifications and registrations such as Europe's CE IVD certification, United States' US-FDA Registration, and China's CFDA Registration via our Chinese partner
- Expansion of ClearCell[®] FX1 System to EMEA and APAC regions through partnerships with 12 new distributors

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

ANNEX A



"Clearbridge BioMedics is leading a transformation around cancer treatments focused on non-invasive liquid biopsy. This enables real-time analysis of wholly intact cancer cells from a standard blood draw, enabling medical professionals to better understand and manage their patients, and potentially improving cancer disease management and outcomes.

This pre-IPO funding will enable us to accelerate our growth and create a differentiated, cost-effective and sustainable model of diagnostic solutions in Asia. Barring unforeseen circumstances, we look forward to launching our IPO in the last quarter of 2018." **said Mr Johnson Chen, Chairman and Founder of Clearbridge BioMedics.**

With a veteran leadership team who bring together strong business, clinical, and engineering capabilities to execute on a unique core technology and scalable business model, Clearbridge BioMedics is a spin-off from the National University of Singapore / SMART MIT and it is the first incubatee of Clearbridge Accelerator (now known as Clearbridge Health Limited [SGX:1H3], a company listed on the Singapore Exchange), a high-technology incubator backed by the Singapore Government's National Research Foundation and Enterprise Singapore.

– END –

About Clearbridge BioMedics

Clearbridge BioMedics Pte Ltd. is a clinical stage cancer diagnostics company that develops and manufactures liquid biopsy systems. Clearbridge BioMedics is based in Singapore and has commercially launched the ClearCell® FX platform to laboratories around the globe. Clearbridge BioMedics has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX System. The ClearCell® FX System and its biochip are utilizing state-of-the-art, non-invasive liquid biopsy to analyze blood samples for circulating tumor cells (CTCs). The device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies.

Clearbridge BioMedics has received ISO 13485 certification in 2011 and the ClearCell® FX System attained CE IVD in 2015 and US FDA Class 1 registration in 2017. In China, the same system is available as China FDA approved Class 1 system as the EasyCell system, through a partnership with MGI (an associate of Beijing Genomics Institute (BGI)).

For more information, visit www.ClearbridgeBioMedics.com.
Product Video <https://youtu.be/6go64NOgaRk>

Media & Investor Contact

Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com